Recent Updates
Recently added Catalysts
XTNT Positive Sentiment

Xtant Medical Announces Second Quarter Revenue Growth of 32%

Tuesday, August 1, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xtant Medical Holdings, Inc. reported a 32% increase in revenue for the second quarter of 2023. The company has raised its annual revenue guidance to between $75 million and $77 million. This growth reflects Xtant's commitment to providing innovative surgical solutions for spinal disorders.
Price reaction · baseline $0.9259 (2023-07-31 close) · hit pre-market · clean, no other XTNT news in the window
day 0 close
+13.4%
day 1 · peak
+17.7%
day 3
+11.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Second quarter revenue growth of 32%
  • Raised annual revenue guidance to $75M - $77M
  • Strong focus on surgical solutions for spinal disorders

Full Press Release Details

Raises 2023 Annual Revenue Guidance to $75 Million – $77 Million BELGRADE, Mont. , Aug. 01, 2023 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported

Frequently Asked Questions

What was Xtant Medical's revenue growth in Q2 2023?

Xtant Medical reported a 32% revenue growth in the second quarter of 2023.

What is the new revenue guidance for 2023?

The company raised its annual revenue guidance to between $75 million and $77 million.

What focus does Xtant Medical have?

Xtant Medical focuses on surgical solutions for the treatment of spinal disorders.

ShareAdd on Google
Tags: XTNT Viatris Investor Conferences Healthcare Xtant Medical revenue growth spinal disorders surgical solutions
Last updated: Aug 1, 2023

Biotech snapshot

Cash runway
$10M liquidity · $2M/mo burn
~4 mo
High dilution risk